Phase 2a data show no dose-limiting toxicities with SLS009 among patients with relapsed/refractory acute myeloid leukemia.
Roman Fabbricatore
Advertisement
Articles by Roman Fabbricatore
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
2
Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment
3
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
4
Searching for Synergy in Liver-Dominant Neuroendocrine Tumors
5
